Lomustine

Also known as: Lomustinum, Lomustina

Drug #1974

LOMUSTINE is a type of chemotherapy for treating cancer. Lomustine belongs to a group of medicines known as alkylating agents. Lomustine interferes with cell growth and is used to treat brain tumors and certain cancers of the blood (Hodgkin's disease). Generic lomustine capsules are not yet available.

← Previous drug Next drug →

Primary Characteristics

Lomustine is also known as Lomustinum, Lomustina.

Molecular Weight: 233.7 · Solubility in Water: Insoluble · Solubility in Alcohol: Soluble · Non-proprietary name: Lomustine.

Pharmacokinetics

Distribution: Lomustine has a plasma protein binding is 50%.

Elimination: it is metabolised via Hepatic, plasma half-life is 94 mins, renal excretion is Urine.

Indications

Lomustine is primarily indicated in conditions like Brain tumors, Hodgkin's disease.

Lomustine is also indicated for secondary conditions like Breast cancer, Lung cancer, Multiple myeloma, Non-hodgkin's lymphoma, Non-hodgkin's lymphoma, Ovarian cancer, Pancreatic cancer, Renal carcinoma.

Contraindications

Lomustine is contraindicated in conditions like Hypersensitivity to any component of product.

Dosage

Lomustine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
115 mg/m2	115 mg/m2	—	PO	every 6 weeks
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Lomustine in overdosage may give rise to further complications which include Pregnancy.

The signs and symptoms that are produced after acute overdosage of Lomustine are Hypoxaemia, Yellow skin, Sore throat, Liver dysfunction, Bruising, Pulmonary toxicity.

Lomustine is known to cause more or less tolerable side effects which are usually transient. These include Confusion, Hair loss, Lethargy, Loss of appetite, Mouth sores, Nausea and vomiting.

Warnings / Precautions

Since the major toxicity is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose. Liver and renal function tests should be monitored periodically. For all instances where the use of lomustine is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risks of toxic effects or adverse reactions. Reinstitution of lomustine therapy should be carried out with caution, and with adequate consideration of the further need for the drug and alertness as to possible recurrence of toxicity.

Interference in Pathology

Lomustine may interfere in the diagnosis of Liver Function Test (LFT) , Periodic blood count, Monitoring of renal function.

Available Brands

None recorded.

Storage Conditions

Lomustine should be stored Tablets.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs